Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:IMTX

Immatics Q1 2025 Earnings Report

Immatics logo
$8.37 +0.04 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$8.38 +0.01 (+0.12%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immatics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Immatics Revenue Results

Actual Revenue
$20.12 million
Expected Revenue
$14.92 million
Beat/Miss
Beat by +$5.20 million
YoY Revenue Growth
N/A

Immatics Announcement Details

Quarter
Q1 2025
Date
5/13/2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Immatics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immatics' Q1 2025 Press ReleasePress Release
(8-K)

Immatics Earnings Headlines

Critical Analysis: MiMedx Group (NASDAQ:MDXG) versus Immatics (NASDAQ:IMTX)
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036713
Immatics N.V. (NASDAQ:IMTX) Receives $20.60 Consensus PT from Brokerages
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034146
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
September 25 at 1:00 AM  |  Stansberry Research (Ad)
Immatics and 4 more stocks see action from activist investors
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/immatics-and-4-more-stocks-see-action-from-activist-investors/ar-AA2bAJ2g
Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=marketbeat.com&utm_medium=referral
Immatics N.v Share Price (IMTX.US)
August 25, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=IMTX.US
See More Immatics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email.

About Immatics

Immatics (NASDAQ:IMTX) is a biopharmaceutical company focused on developing T cell receptor (TCR)-based therapies for cancer. The company aims to identify cancer targets that are presented on the surface of tumor cells and develop treatments that enable T cells to recognize and attack those cells, including targets that may be difficult to address with conventional antibody-based medicines.

Immatics’ technology platforms support two primary approaches: TCR-engineered T-cell therapies, known as TCR-T, and TCR-based bispecific molecules designed to direct patients’ T cells toward tumor cells. Its pipeline has included investigational programs targeting cancer-associated antigens such as PRAME, with potential applications across solid tumors and other cancers. These programs remain subject to clinical development and regulatory review.

Founded in 2000, Immatics is headquartered in Tübingen, Germany, and operates internationally, serving the global biopharmaceutical market through its research, clinical-development and strategic collaboration activities. The company’s leadership includes Harpreet Singh, Ph.D., who serves as chief executive officer. Immatics’ American depositary shares trade on the Nasdaq Global Select Market under the symbol “IMTX.”

View Immatics Profile
Earnings Tools